

November 6, 2023



# DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its third quarter 2023 financial results will be released after the markets close on Monday, November 13<sup>th</sup>. DiaMedica will host a live conference call on Tuesday, November 14<sup>h</sup> at 7:00 AM Central Time to provide a business update and discuss financial results.

## Conference Call details:

|                |                                                                                       |
|----------------|---------------------------------------------------------------------------------------|
| Date:          | Tuesday, November 14, 2023                                                            |
| Time:          | 7:00 AM CT / 8:00 AM ET                                                               |
| Web access:    | <a href="https://app.webinar.net/OVpdLmgYMDE">https://app.webinar.net/OVpdLmgYMDE</a> |
| Dial In:       | (877) 550-1858                                                                        |
| Conference ID: | 1754341                                                                               |

Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for playback on our website, under investor relations - events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until November 21, 2023, by dialing (800) 645-7964 (US Toll Free) and entering the replay passcode: 2125#.

## ***About DiaMedica Therapeutics Inc.***

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. DiaMedica's lead candidate DM199 is the first pharmaceutically active and clinically studied recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke and other vascular diseases. For more information visit our website at [www.diamedica.com](http://www.diamedica.com).

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20231106951994/en/>

Scott Kellen  
Chief Financial Officer  
Phone: (763) 496-5118  
[skellen@diamedica.com](mailto:skellen@diamedica.com)

Paul Papi  
Corporate Communications  
Phone: 617-899-5941  
[ppapi@diamedica.com](mailto:ppapi@diamedica.com)

Source: DiaMedica Therapeutics Inc.